Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s
Video

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Launching: Thursday 24th April 2025
 
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in:

Open Access 17-07-2024 | Diffuse Large B-Cell Lymphoma | Review Article

Advances in biology, diagnosis and treatment of DLBCL

Authors: Yuanfei Shi, Yi Xu, Huafei Shen, Jie Jin, Hongyan Tong, Wanzhuo Xie

Published in: Annals of Hematology | Issue 9/2024

Login to get access

Abstract

Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) has identified at least three major subtypes of DLBCL, each of which has distinct clinical, biological, and genetic features: activated B-cell (ABC)-like DLBCL, germinal-center B-cell (GCB)-like DLBCL, and unclassified. Different origins are associated with different responses to chemotherapy and targeted agents. Despite DLBCL being a highly heterogeneous disease, more than 60% of patients with DLBCL can be cured after using rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) to inhibit the growth of cancer cells while targeting the CD20 receptor. In recent decades, the improvement of diagnostic levels has led to a refinement classification of DLBCL and the development of new therapeutic approaches. The objective of this review was to summarize the latest studies examining genetic lesions and therapies for DLBCL.
Literature
1.
2.
Roschewski M, Staudt LM, Wilson WH (2014) Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11(1):12–23PubMed
3.
Coiffier B et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242PubMed
4.
Alaggio R et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7): 1720–1748
5.
Martinez-Climent JA et al (2003) Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101(8):3109–3117PubMed
6.
Kridel R et al (2017) Predicting transformation of follicular lymphoma. Blood 130(3):258–266PubMed
7.
Bouska A et al (2014) Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood 123(11):1681–1690PubMedPubMedCentral
8.
9.
Rossi D, Gaidano G (2009) Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 27(1):1–10PubMed
10.
Chigrinova E et al (2013) Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 122(15):2673–2682PubMed
11.
Tiirikainen MI et al (2001) DNA copy number alterations in HIV-positive and HIV-negative patients with diffuse large-cell lymphomas. J Acquir Immune Defic Syndr 27(3):272–276PubMed
12.
Gucalp A, Noy A (2010) Spectrum of HIV lymphoma 2009. Curr Opin Hematol 17(4):362–367PubMed
13.
Carbone A et al (2001) Genetic pathways and histogenetic models of AIDS-related lymphomas. Eur J Cancer 37(10):1270–1275PubMed
14.
Frontzek F, Lenz G (2019) Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev Clin Pharmacol 12(11):1059–1067PubMed
15.
Chapuy B et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679–690PubMedPubMedCentral
16.
17.
Wright GW et al (2020) A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37(4):551-568 e14PubMedPubMedCentral
18.
Barraclough A et al (2019) COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Adv 3(13):2013–2021PubMedPubMedCentral
19.
Kumar A et al (2015) Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era. Br J Haematol 171(5):776–783PubMedPubMedCentral
20.
Cunningham D et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817–1826PubMed
21.
Scott DW et al (2015) Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol 33(26):2848–2856PubMedPubMedCentral
22.
Augustyn A et al (2021) The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1361–1369PubMedPubMedCentral
23.
Johnson NA et al (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114(11):2273–2279PubMedPubMedCentral
24.
Scott DW et al (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131(18):2060–2064PubMedPubMedCentral
25.
26.
Alizadeh AA et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511PubMed
27.
Wright G et al (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 100(17):9991–9996PubMedPubMedCentral
28.
Rosenwald A et al (2003) Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198(6):851–862PubMedPubMedCentral
29.
30.
Rosenwald A et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947PubMed
31.
Visco C et al (2012) Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 26(9):2103–2113PubMedPubMedCentral
32.
Guo L et al (2018) Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment. Biochim Biophys Acta Rev Cancer 1869(2):85–96PubMed
33.
Wilson WH et al (2012) A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 97(5):758–765PubMedPubMedCentral
34.
Monti S et al (2005) Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105(5):1851–1861PubMed
35.
36.
Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214–218PubMedPubMedCentral
37.
Morin RD et al (2013) Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood 122(7):1256–1265PubMedPubMedCentral
38.
39.
40.
Saito M et al (2009) BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci USA 106(27):11294–11299PubMedPubMedCentral
41.
Pasqualucci L et al (2001) Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 412(6844):341–346PubMed
42.
Cattoretti G et al (2005) Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice. Cancer Cell 7(5):445–455PubMed
43.
Iqbal J et al (2007) Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 21(11):2332–2343PubMedPubMedCentral
44.
Saito M et al (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12(3):280–292PubMed
45.
Juszczynski P et al (2009) BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase. PTPROt Blood 114(26):5315–5321PubMed
46.
Basso K et al (2012) BCL6 positively regulates AID and germinal center gene expression via repression of miR-155. J Exp Med 209(13):2455–2465PubMedPubMedCentral
47.
Chen YW et al (2006) High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood 108(7):2373–2383PubMed
48.
Ott G et al (2010) Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116(23):4916–4925PubMed
49.
Horn H et al (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121(12):2253–2263PubMed
50.
Winter JN et al (2006) Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 107(11):4207–4213PubMedPubMedCentral
51.
Oki Y et al (2008) Prognostic value of serum soluble interleukin-2 receptor level in patients with diffuse large B cell lymphoma, treated with CHOP- or RCHOP-based therapy. Leuk Lymphoma 49(7):1345–1351PubMed
52.
Akyurek N et al (2012) Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer 118(17):4173–4183PubMed
53.
Copie-Bergman C et al (2009) Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 27(33):5573–5579PubMed
54.
Mandelbaum J et al (2010) BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 18(6):568–579PubMedPubMedCentral
55.
Compagno M et al (2009) Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 459(7247):717–721PubMedPubMedCentral
56.
Kato M et al (2009) Frequent inactivation of A20 in B-cell lymphomas. Nature 459(7247):712–716PubMed
57.
Calado DP et al (2010) Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell 18(6):580–589PubMedPubMedCentral
58.
Lenz G et al (2008) Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 105(36):13520–13525PubMedPubMedCentral
59.
Lenz G et al (2007) Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 204(3):633–643PubMedPubMedCentral
60.
Shaffer AL et al (2002) Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17(1):51–62PubMed
61.
Lohr JG et al (2012) Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 109(10):3879–3884PubMedPubMedCentral
62.
Lenz G et al (2008) Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676–1679PubMed
63.
Davis RE et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463(7277):88–92PubMedPubMedCentral
64.
Ngo VN et al (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115–119PubMed
65.
Cao R et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298(5595):1039–1043PubMed
66.
Bonetti P et al (2013) Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. Blood 122(13):2233–2241PubMed
67.
Scuto A et al (2011) STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 71(9):3182–3188PubMedPubMedCentral
68.
Ding BB et al (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3):1515–1523PubMedPubMedCentral
69.
Nogai H et al (2013) IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL. Blood 122(13):2242–2250PubMed
70.
Iqbal J et al (2004) BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 165(1):159–166PubMedPubMedCentral
71.
Iqbal J et al (2011) BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res 17(24):7785–7795PubMedPubMedCentral
72.
Visco C et al (2013) Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 98(2):255–263PubMedPubMedCentral
73.
Klapper W et al (2012) Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood 119(8):1882–1887PubMed
74.
Kendrick SL et al (2014) BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Hum Pathol 45(10):2144–2153PubMedPubMedCentral
75.
Schuetz JM et al (2012) BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 26(6):1383–1390PubMed
76.
de Jong D et al (2009) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 62(2):128–138PubMed
77.
de Jong D et al (2007) Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications–a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 25(7):805–812PubMed
78.
Iqbal J et al (2006) BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24(6):961–968PubMed
79.
Pasqualucci L et al (2011) Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 471(7337):189–195PubMedPubMedCentral
80.
81.
Morin RD et al (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42(2):181–185PubMedPubMedCentral
82.
McCabe MT et al (2012) Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci USA 109(8):2989–2994PubMedPubMedCentral
83.
Qi W et al (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 109(52):21360–21365PubMedPubMedCentral
84.
McCabe MT et al (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427):108–112PubMed
85.
Knutson SK et al (2012) A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8(11):890–896PubMed
86.
Kant S, Kumar A, Singh SM (2014) Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype. Biochim Biophys Acta 1840(1):294–302PubMed
87.
Cayrol F et al (2015) Integrin alphavbeta3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood 125(5):841–851PubMedPubMedCentral
88.
Ciavarella S et al (2019) Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 30(12):2015PubMedPubMedCentral
89.
Ciavarella S et al (2018) Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 29(12):2363–2370PubMedPubMedCentral
90.
de Charette M, Houot R (2018) Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy. Haematologica 103(8):1256–1268PubMedPubMedCentral
91.
Pandey S et al (2017) IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood 129(18):2507–2518PubMed
92.
Kotlov N et al (2021) Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer Discov 11(6):1468–1489PubMedPubMedCentral
93.
Becht E et al (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218PubMedPubMedCentral
94.
Sabattini E et al (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83–87PubMed
95.
Hans CP et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282PubMed
96.
97.
Keane C et al (2013) CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am J Hematol 88(4):273–276PubMed
98.
Meyer PN et al (2011) The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab. Am J Clin Pathol 135(1):54–61PubMed
99.
Niitsu N et al (2011) A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Ann Hematol 90(2):185–192PubMed
100.
Green TM et al (2012) Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3460–3467PubMed
101.
Johnson NA et al (2012) Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 30(28):3452–3459PubMedPubMedCentral
102.
Hu S et al (2013) MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121(20): 4021–31; quiz 4250
103.
Staiger AM et al (2017) Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group. J Clin Oncol 35(22):2515–2526PubMed
104.
Choi WW et al (2009) A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15(17):5494–5502PubMedPubMedCentral
105.
Muris JJ et al (2006) Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 208(5):714–723PubMed
106.
Nyman H et al (2007) Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109(11):4930–4935PubMed
107.
Natkunam Y et al (2008) LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 26(3):447–454PubMed
108.
Meyer PN et al (2011) Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol 29(2):200–207PubMed
109.
Hawkes EA, Barraclough A, Sehn LH (2022) Limited-stage diffuse large B-cell lymphoma. Blood 139(6):822–834PubMed
110.
Chaganti S et al (2016) Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol 174(1):43–56PubMed
111.
Sehn LH, Salles G (2021) Diffuse Large B-Cell Lymphoma. Reply N Engl J Med 384(23):2262PubMed
112.
Chiodin G et al (2021) Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behavior. Blood 138(17):1570–1582PubMedPubMedCentral
113.
Rovida A et al (2021) Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia. Clin Cancer Res 27(3):729–739PubMed
114.
Wang L et al (2022) Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study. Br J Dermatol
115.
Koo M et al (2022) Human Germinal Center-associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma. Am J Surg Pathol 46(5):643–654PubMed
116.
Loeffler-Wirth H et al (2022) Classifying germinal center derived lymphomas—Navigate a complex transcriptional landscape. Cancers (Basel) 14(14)
117.
Pindzola GM et al (2022) Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma. Blood
118.
Amanda S et al (2022) IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma. Nat Commun 13(1):2420PubMedPubMedCentral
119.
Frauenfeld L et al (2022) Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Adv 6(7):2361–2372PubMedPubMedCentral
120.
Ricker E et al (2020) Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Sci Rep 10(1):13094PubMedPubMedCentral
121.
Horn H et al (2015) Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia 29(7):1564–1570PubMed
122.
Khanlari M et al (2022) Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge. Mod Pathol 35(3):419–426PubMed
123.
Fang H et al (2022) Reactive Intralymphovascular Immunoblastic Proliferations Mimicking Aggressive Lymphomas. Am J Surg Pathol 46(3):326–335PubMed
124.
Minakata D et al (2018) A leukemic double-hit follicular lymphoma associated with a complex variant translocation, t(8;14;18)(q24;q32;q21), involving BCL2, MYC, and IGH. Cancer Genet 220:44–48PubMed
125.
Tan DE et al (2013) Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet 45(7):804–807PubMed
126.
Strazza M et al (2021) PD-1-induced proliferating T cells exhibit a distinct transcriptional signature. Immunology 164(3):555–568PubMedPubMedCentral
127.
Li J et al (2021) Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma. Med Oncol 38(4):33PubMedPubMedCentral
128.
Gonzalez-Figueroa P et al (2021) Follicular regulatory T cells produce neuritin to regulate B cells. Cell 184(7):1775-1789 e19PubMed
129.
Jo T et al (2020) LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells. Blood 136(6):684–697PubMed
130.
Bucher P et al (2020) Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma. Blood 135(2):121–132PubMed
131.
Yang Y et al (2016) Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma. Cancer Cell 29(4):494–507PubMedPubMedCentral
132.
Duns G et al (2021) Characterization of DLBCL with a PMBL gene expression signature. Blood 138(2):136–148PubMed
133.
Watanabe T (2021) The tumor microenvironment in follicular lymphoma: its pro-malignancy role with therapeutic potential. Int J Mol Sci 22(10)
134.
Cheson BD et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068PubMedPubMedCentral
135.
El-Galaly TC et al (2018) FDG-PET/CT in the management of lymphomas: current status and future directions. J Intern Med 284(4):358–376PubMed
136.
Adams HJ et al (2014) FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 41(3):565–574PubMed
137.
Persky DO et al (2020) Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001. J Clin Oncol 38(26):3003–3011PubMedPubMedCentral
138.
Lamy T et al (2018) R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood 131(2):174–181PubMedPubMedCentral
139.
Persky DO et al (2008) Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26(14):2258–2263PubMed
140.
Roschewski M, Phelan JD, Jaffe ES (2024) Primary large b-cell lymphomas of immune-privileged sites. Blood 14(3):345–357
141.
Pfreundschuh M et al (2011) CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 12(11):1013–1022PubMed
142.
Shahbazi S, Peer CJ, Figg WD (2014) Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy. Cancer Biol Ther 15(9):1117–1119PubMedPubMedCentral
143.
Odejide OO et al (2015) Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma 56(3):716–724PubMed
144.
Kwon J et al (2015) Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys 92(1):91–98PubMed
145.
Wiernik PH et al (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26(30):4952–4957PubMed
146.
Nowakowski GS et al (2015) Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol 33(3):251–257PubMed
147.
Vitolo U et al (2014) Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 15(7):730–737PubMed
148.
Nowakowski GS et al (2021) Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol 39(12):1329–1338PubMedPubMedCentral
149.
Nowakowski GS et al (2021) ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 39(12):1317–1328PubMedPubMedCentral
150.
Leonard JP et al (2017) Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. J Clin Oncol 35(31):3538–3546PubMed
151.
Wilson WH et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922–926PubMedPubMedCentral
152.
Elstrom RL et al (2008) Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol 19(10):1770–1773PubMedPubMedCentral
153.
Cheah CY et al (2013) Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109(2):312–317PubMedPubMedCentral
154.
Cheung MC et al (2018) Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission. Clin Lymphoma Myeloma Leuk 18(1):e27–e34PubMed
155.
Sehn LH (2012) Chemotherapy alone for localized diffuse large B-cell lymphoma. Cancer J 18(5):421–426PubMed
156.
Devic S et al (2010) Defining radiotherapy target volumes using 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography: still a Pandora’s box? Int J Radiat Oncol Biol Phys 78(5):1555–1562PubMed
157.
Andre MPE et al (2017) Early positron emission tomography response–adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 35(16):1786–1794PubMed
158.
Mikhaeel NG et al (2016) Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging 43(7):1209–1219PubMedPubMedCentral
159.
Zhao P, Yu T, Pan Z (2021) Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann Nucl Med 35(1):24–30PubMed
160.
Wilson WH et al (2021) Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(12):1643-1653 e3PubMedPubMedCentral
161.
Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184–4190PubMedPubMedCentral
162.
Gonzalez Barca E (2023) Developing new strategies for relapsed/refractory diffuse large B-Cell lymphoma. J Clin Med 12(23):173–187
163.
Crump M et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808PubMedPubMedCentral
164.
Chavez JC, Bachmeier C, Kharfan-Dabaja MA (2019) CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol 10:2040620719841581PubMedPubMedCentral
165.
Sermer D et al (2020) Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Adv 4(19):4669–4678PubMedPubMedCentral
166.
Kochenderfer JN et al (2017) Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 25(10):2245–2253PubMedPubMedCentral
167.
Siddiqi T et al (2023) Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. Lancet 402(10402):641–654PubMed
168.
Abramson JS et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839–852PubMed
169.
Schuster SJ et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56PubMed
170.
Neelapu SS et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544PubMedPubMedCentral
171.
Westin J, Sehn LH (2022) CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood 139(18):2737–2746PubMed
172.
Kuhnl A et al (2022) A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience. Br J Haematol 198(3):492–502PubMed
173.
Al-Mashhadi AL et al (2024) Real-world outcomes following third or subsequent lines of therapy: A Danish population-based study on 189 patients with relapsed/refractory large B-cell lymphomas. Br J Haematol 204(3):839–848PubMed
174.
Locke FL et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20(1):31–42PubMed
175.
Lin JK et al (2019) Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol 37(24):2105–2119PubMed
176.
Czuczman MS et al (2017) A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 23(15):4127–4137PubMedPubMedCentral
177.
Davids MS et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826–833PubMedPubMedCentral
178.
Zauderer MG et al (2022) EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Lancet Oncol 23(6):758–767PubMed
179.
Harrington F et al (2021) Genomic characterisation of diffuse large B-cell lymphoma. Pathology 53(3):367–376PubMed
180.
Tilly H et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351–363PubMed
181.
Lee A (2021) Loncastuximab tesirine: first approval. Drugs 81(10):1229–1233PubMed
182.
Caimi PF et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22(6):790–800PubMed
183.
Kalakonda N et al (2020) Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 7(7):e511–e522PubMed
184.
Zinzani PL et al (2021) RE-MIND: comparing tafasitamab+ lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res 27(22):6124–6134PubMedPubMedCentral
185.
Locke FL et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 386(7):640–654PubMed
186.
Budde LE et al (2022) Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol 23(8):1055–1065PubMed
187.
Hutchings M et al (2021) Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol 39(18):1959–1970PubMedPubMedCentral
188.
Hutchings M et al (2021) Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 398(10306):1157–1169PubMed
189.
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723PubMedPubMedCentral
190.
Robert C et al (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517–2526PubMed
191.
Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153–167PubMed
192.
Metadata
Title
Advances in biology, diagnosis and treatment of DLBCL
Authors
Yuanfei Shi
Yi Xu
Huafei Shen
Jie Jin
Hongyan Tong
Wanzhuo Xie
Publication date
17-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 9/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05880-z

Other articles of this Issue 9/2024

The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease

Speckle tracking echocardiography and β-thalassemia major. A systematic review

Lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 86 patients

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide-based regimen for prevention of graft-versus-host disease in haploidentical peripheral blood stem cell transplantation for pediatric patients with hematologic malignancies

The roles of ubiquitination in AML

Mutations of epigenetic modifier genes predict poor outcome in adult acute lymphoblastic leukemia

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Incorporating comprehensive genomic profiling into the standard-of-care for NSCLC and thyroid cancer

In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.

This content is intended only for US-based healthcare providers.

Supported by:
  • Illumina, Inc., and Eli Lilly and Company
Dr. Vivek Subbiah
Dr. Alexander Drilon
Dr. Michelle Williams
Developed by: Springer Healthcare
Watch now
Video

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
Image Credits